Lucas is an Industry veteran who brings expertise in commercialization, operations, business development, and finance to Procyrion as it continues to focus on its DRAIN-HF pivotal IDE trial and begins preparation for US commercialization of its Aortix percutaneous mechanical circulatory support (pMCS) technology.
Procyrion Announces Appointment of Lucas Buchanan to Board of Directors Read More »
Provider status with Medi-Cal will allow Mindera Health to provide its proprietary Mind.Px test to predict biologic class response in plaque psoriasis to the over 15 million Medi-Cal Beneficiaries. San Diego, CA, Aug 19, 2024 (GLOBE NEWSWIRE) — Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has completed the credentialling
Mindera Health™ becomes a Medi-Cal™ Credentialled Provider Read More »
Mindera Health is disrupting the world of medicine. Ashley takes you inside their Carlsbad headquarters to see how this new psoriasis predictive test is changing lives for the better. Mindera Health founder Toby Dickerson explains it all. See More: Precision Medicine disrupts the medical world | FOX 5 San Diego & KUSI News The
THE LOCALIST SD Precision Medicine disrupts the medical world Read More »
Koya Medical, today announces topline results from its TEAYS trial. TEAYS (NCT05507346) is a prospective multi-center, randomized cross-over study comparing lower extremity lymphedema treatment effectiveness of Dayspring?, Koya’s non-pneumatic compression device (NPCD) with a traditional advanced pneumatic compression device (APCD). The study met its primary endpoints, achieving statistically significant differences in limb volume reduction,
Koya Medical Announces Topline Results from Its Latest Trial Read More »
Procyrion is proud to be recognized as a Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix™ technology and the potential it has to change the way patients with acute decompensated heart failure and cardiorenal syndrome are treated. Read more…
Procyrion Recognized in Fierce Medtech’s Fierce15 of 2023 Read More »
Innovative collaboration will improve patient outcomes and cost savings through reduced trial-and-error management of biologic therapies Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with LivinitiTM, an innovative Pharmacy Benefit Manager, to improve the management of moderate-to-severe psoriasis patients. This pilot program will utilize Mind.Px to
Podimetrics – Revolutionize diabetic foot care for your patients Skip to main content Skip to footer Download our new eBook today! Breaking Barriers: Combatting Diabetic Amputations in Communities of ColorPeople of Color bear the heaviest
Revolutionize diabetic foot care for your patients Read More »
HOUSTON, TX – February 5, 2024 – Procyrion™, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing. These funds will be used to support the ongoing DRAIN-HF
Procyrion Closes $57.7 Million in Series E Financing Read More »
February 2, 2024 – Woburn, MA Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will be participating in the 2024 International Master Course on Aging Science (IMCAS) World Congress, taking place February 1 – 3, 2024, in Paris. Chief Executive Officer and President, Jon
Eirion Therapeutics to Present at the 2024 IMCAS World Congress Read More »
HOUSTON, TX – NOVEMBER 30, 2023 – Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first patients in the company’s IDE pivotal trial. The DRAIN-HF (Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure) study will evaluate the Aortix™ percutaneous